Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3 mutation-positive leukemia

[1]  A. Agarwal,et al.  RNAi Screening of Leukemia Cells Using Electroporation. , 2016, Methods in molecular biology.

[2]  Naomi A. Sengamalay,et al.  Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma , 2015, PloS one.

[3]  M. Stern,et al.  Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia , 2014, Leukemia.

[4]  S. Miyano,et al.  Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia , 2013, Nature Genetics.

[5]  J. Sandow,et al.  Signalling by the βc family of cytokines. , 2013, Cytokine & growth factor reviews.

[6]  W. Vainchenker,et al.  JAK/STAT signaling in hematological malignancies , 2013, Oncogene.

[7]  Z. Zhao,et al.  A Functional Thrombopoietin Receptor Is Required for Full Expression of Phenotype in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera , 2012 .

[8]  V. Pistoia,et al.  Targeting acute myeloid leukemia cells with cytokines , 2012, Journal of leukocyte biology.

[9]  M. Heinrich,et al.  Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia , 2012, Leukemia.

[10]  J. O’Shea,et al.  Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. , 2012, Current opinion in pharmacology.

[11]  R. Pieters,et al.  Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia , 2011, Leukemia.

[12]  T. Waldmann,et al.  CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. , 2011, Blood.

[13]  R. Venkataramanan,et al.  Treating inflammation with the Janus kinase inhibitor CP-690,550. , 2011, Trends in pharmacological sciences.

[14]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[15]  T. Boggon,et al.  JAK3: a two-faced player in hematological disorders. , 2009, The international journal of biochemistry & cell biology.

[16]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[17]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[18]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[19]  J. Rubin,et al.  Chemokine signaling in cancer: one hump or two? , 2009, Seminars in cancer biology.

[20]  Y. Chung,et al.  Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.

[21]  H. Kanegane,et al.  Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome , 2008, British journal of haematology.

[22]  M. Tomasson,et al.  The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. , 2008, Blood.

[23]  C. Pecquet,et al.  Mining for JAK-STAT mutations in cancer. , 2008, Trends in biochemical sciences.

[24]  B. Druker,et al.  RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. , 2008, Blood.

[25]  A. Tefferi.  JAK and MPL mutations in myeloid malignancies , 2008, Leukemia & lymphoma.

[26]  J. Ihle,et al.  Jak2 FERM Domain Interaction with the Erythropoietin Receptor Regulates Jak2 Kinase Activity , 2007, Molecular and Cellular Biology.

[27]  R. A. Etten.  Aberrant cytokine signaling in leukemia , 2007, Oncogene.

[28]  D. Nižetić,et al.  Loss‐of‐function JAK3 mutations in TMD and AMKL of Down syndrome , 2007, British journal of haematology.

[29]  T. Naoe,et al.  JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults , 2007, Leukemia.

[30]  R. V. van Etten,et al.  Aberrant cytokine signaling in leukemia. , 2007, Oncogene.

[31]  Hartmut Döhner,et al.  Acute myeloid leukaemia , 2006, The Lancet.

[32]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[33]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[34]  James M. Murphy,et al.  IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. , 2006, Vitamins and hormones.

[35]  J. O’Shea,et al.  New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway , 2005, Current opinion in rheumatology.

[36]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[37]  J. O’Shea,et al.  Jak3-Independent Trafficking of the Common γ Chain Receptor Subunit: Chaperone Function of Jaks Revisited , 2004, Molecular and Cellular Biology.

[38]  M. Graf,et al.  Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies , 2004, European journal of haematology.

[39]  P. Kovacs,et al.  Leukemic cells and the cytokine patchwork , 2004, Pediatric blood & cancer.

[40]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[41]  J. Thèze,et al.  Critical sites for the interaction between IL-2Rgamma and JAK3 and the following signaling. , 2001, Biochemical and biophysical research communications.

[42]  J. Johnston,et al.  Autosomal SCID caused by a point mutation in the N‐terminus of Jak3: mapping of the Jak3–receptor interaction domain , 1999, The EMBO journal.

[43]  L. Berg,et al.  T cell development and activation in Jak3‐deficient mice , 1998, Journal of leukocyte biology.

[44]  J. Johnston,et al.  In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction , 1996, The Journal of experimental medicine.